Fanny Turon

Fanny Turon

Auto-generated profile, based on publicly available information

Fanny Turon

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Clínic Barcelona, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver), CSUR Centro de referencia del Sistema Nacional de Salud en Enfermedad Hepática Compleja. Barcelona, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
MMMarta Magaz
Marta Magaz
HGHeloïse Giudicelli-Lett
Heloïse Giudicelli-Lett
JAJuan G. Abraldes
Juan G. Abraldes
OFOANA FARCAU-NICOARA
OANA FARCAU-NICOARA
FTFanny Turon
Fanny Turon
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán

11 July 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
EDEllen G. Driever
Ellen G. Driever
MMMarta Magaz
Marta Magaz
JAJelle Adelmeijer
Jelle Adelmeijer
FTFanny Turon
Fanny Turon
ABAnna Baiges
Anna Baiges
TLTon Lisman
Ton Lisman
A hypercoagulable state is not associated with development of portal vein thrombosis in cirrhosis, as we previously demonstrated. However, some groups demonstrated elevated levels of inflammatory markers and activation of hemostasis in the portal vein (PV) compared to posthepatic veins, but because the liver is involved in clearance of these markers, we hypothesize that interpretation of these data is not straightforward. To determine whether the PV has particular proinflammatory/hypercoagulable characteristics by comparing plasma sampled in the PV, hepatic vein (HV), and the systemic circulation. Plasma samples from 51 cirrhotic patients with portal hypertension undergoing transjugular intrahepatic portosystemic shunt placement, were taken from the PV, HV, and jugular vein (JV). Markers of inflammation (lipopolysaccharide, tumor necrosis factor‐α, interleukin‐6, thiobarbituric acid‐reactive substances), neutrophil‐extracellular‐traps (cfDNA, MPO‐DNA), endothelial damage (von Willebrand factor [VWF]), and hemostasis were determined and compared among the three vascular beds. Markers of inflammation were slightly, but significantly higher in the PV than in the HV and systemic circulation. VWF and markers of hemostasis were modestly elevated in the PV. Levels of multiple markers were lower in the HV compared with the PV and systemic circulation. Higher model for end‐stage liver disease score was associated with a more prothrombotic state in all three sample sites. In contrast to published studies, we did not detect a clear proinflammatory or prothrombotic environment in the PV of cirrhotic patients. Many markers are lowest in the HV, indicating that the low levels of these markers in the HV, at least in part, reflect clearance of those markers in the liver.

9 July 2021 in Liver International
Verified
Journal Article
Closed access
PDF file
MMMattias Mandorfer
Mattias Mandorfer
FTFanny Turon
Fanny Turon
SLSabela Lens
Sabela Lens
ABAnna Baiges
Anna Baiges
ÁGÁngeles García-Criado
Ángeles García-Criado
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán

8 November 2024 in Liver Transplantation
Verified
Journal Article
Closed access
FTFanny Turon
Fanny Turon
SSSarah Shalaby
Sarah Shalaby
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
VHVirginia Hernández-Gea
Virginia Hernández-Gea
Portal vein thrombosis (PVT) is a frequent event among patients with advanced liver disease, with a prevalence reaching up to 26% in those awaiting liver transplantation (LT). Extensive thrombosis affecting the mesenteric vein confluence correlates with increased morbidity and mortality post-LT, particularly when it impedes physiological anastomosis or contraindicates the LT. Current guidelines advocate for routine PVT screening in all potential liver transplant candidates and prompt treatment upon detection. The main objective in LT candidates is to facilitate physiological portal-to-portal anastomosis. Anticoagulation serves as the first-line therapy, achieving recanalization rates between 33 and 75%. Discontinuation of anticoagulation significantly heightens the risk of rethrombosis in a substantial proportion of patients and therefore, it is recommended to continue anticoagulation until LT for those awaiting LT or potential LT candidates. Nevertheless, 30-60% of patients fail to respond to anticoagulation, with PVT progression occurring in up to 14% despite anticoagulation. In such cases, TIPS placement emerges as a viable alternative to maintain portal vein patency. While the feasibility of TIPS placement diminished with the presence of portal cavernoma or chronic portal vein thrombosis, the introduction of novel interventional radiological techniques to recanalize the portal venous axis through transplenic, transmesenteric and/or transhepatic routes is revolutionizing this landscape. These advancements achieve TIPS placement and recanalization in 90-100% of patients, warranting consideration in cirrhotic patients with chronic PVT for whom LT would otherwise be contraindicated or when physiological anastomosis is not feasible. Export